Scroll

aztreonam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monobactam antibiotics	279	78110-38-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cayston aztreonam azonam azthreonam aztreon monobactam nebactam primbactam aztreonam lysine azactam	A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Molecular weight: 435.43 Formula: C13H17N5O8S2 CLOGP: -0.36 LIPINSKI: 1 HAC: 13 HDO: 4 TPSA: 201.58 ALOGS: -3.34 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cayston
aztreonam
azonam
azthreonam
aztreon
monobactam
nebactam
primbactam
aztreonam lysine
azactam

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Molecular weight: 435.43
Formula: C13H17N5O8S2
CLOGP: -0.36
LIPINSKI: 1
HAC: 13
HDO: 4
TPSA: 201.58
ALOGS: -3.34
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.23	g	Inhal.solution
4	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	68 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	305.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	1.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.18 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1986	FDA	BRISTOL MYERS SQUIBB
Sept. 21, 2009	EMA	GILEAD SCIENCES IRELAND UC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	1732.65	24.19	363	7973	8454	63472232
Cystic fibrosis	418.16	24.19	95	8241	3201	63477485
Death	254.26	24.19	277	8059	374104	63106582
Lung transplant	229.73	24.19	58	8278	3070	63477616
Pulmonary function test decreased	216.35	24.19	58	8278	3889	63476797
Haemoptysis	212.55	24.19	94	8242	28632	63452054
Hospitalisation	201.07	24.19	130	8206	84951	63395735
Bacterial disease carrier	194.02	24.19	43	8293	1288	63479398
Bronchial secretion retention	181.94	24.19	47	8289	2726	63477960
Superinfection	160.46	24.19	42	8294	2565	63478121

Showing 1 to 10 of 51 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	907.10	23.74	208	4940	6593	34945190
Cystic fibrosis	355.34	23.74	75	5073	1583	34950200
Lung transplant	307.43	23.74	69	5079	1955	34949828
Death	140.38	23.74	226	4922	397823	34553960
Hospitalisation	125.57	23.74	87	5061	56815	34894968
Eosinophilia	95.21	23.74	55	5093	26167	34925616
Pulmonary function test decreased	89.69	23.74	32	5116	4943	34946840
Cystic fibrosis respiratory infection suppression	87.70	23.74	17	5131	228	34951555
Haemoptysis	80.60	23.74	55	5093	34951	34916832
Pseudomonas infection	79.35	23.74	38	5110	12344	34939439

Showing 1 to 10 of 30 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	2039.29	21.05	450	10874	12401	79720663
Cystic fibrosis	565.17	21.05	127	11197	3753	79729311
Lung transplant	405.04	21.05	100	11224	4461	79728603
Eosinophilia	243.91	21.05	122	11202	45223	79687841
Pulmonary function test decreased	239.82	21.05	74	11250	7563	79725501
Haemoptysis	222.41	21.05	123	11201	55876	79677188
Death	216.17	21.05	328	10996	566186	79166878
Hospitalisation	205.14	21.05	141	11183	94095	79638969
Bacterial disease carrier	184.23	21.05	43	11281	1503	79731561
Bronchial secretion retention	164.42	21.05	48	11276	4056	79729008

Showing 1 to 10 of 70 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DF01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Monobactams
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50696	PBP3 inhibitor
CHEBI has role	CHEBI:88188	allergenic drug
FDA CS	M0014030	Monobactams
FDA EPC	N0000175493	Monobactam Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
Septicemia due to Escherichia coli	indication	9323009
Infection due to Pseudomonas aeruginosa	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Pseudomonas	indication	41381004
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007

Showing 1 to 10 of 62 entries

Previous1 2 3 4 5 6 7Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.44	acidic
pKa2	2.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	5.32	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	4.32	WOMBAT-PK	CHEMBL
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	5.74	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	A4ZYU9_ECOLX		IC50	7.49	CHEMBL
AmpC	Unclassified	Q83TT7_ECOLX		IC50	7.22	CHEMBL
Efflux transporter; SugE	Transporter	Q3S5C3_SALNE		IC50	8.22	CHEMBL
Beta-lactamase	Enzyme	Q48435_KLEPN		IC50	8.22	CHEMBL
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	8.15	CHEMBL
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	5.52	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_PSEAE		IC50	5.48	CHEMBL

Showing 1 to 10 of 11 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
T6O	PDB_CHEM_ID
002807	NDDF
013342	NDDF
10763	IUPHAR_LIGAND_ID
1272	RXNORM
167898	MMSL
170132	MMSL
2813	MMSL
373297006	SNOMEDCT_US
387386004	SNOMEDCT_US

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2560	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
AZACTAM	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2570	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	NDA	21 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0829	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	23 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0830	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	23 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Aztreonam	HUMAN PRESCRIPTION DRUG LABEL	1	63323-401	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections

Showing 1 to 10 of 20 entries

Previous1 2Next